Bioheart, Inc.’s (NASDAQ: BHRT)

Bioheart, Inc.’s (NASDAQ: BHRT) primary mission is to become a leading company focused on discovering, developing and commercializing innovative, autologous cell therapies and such devices. A number of cell therapies and related devices designed to treat chronic and acute heart damage consist of the company’s product line. They believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant as there are approximately 5.2 million patients with heart failure in the United States alone. For further information, visit the Company’s web site at www.bioheartinc.com.